Benjamin Greenberg, MD
Neurology · Dallas, TXNPI 1518922871
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.7%. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 373 payments — averaging $2071.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$183K
- Amgen$152K
- EMD Serono, Inc.$93K
- TG Therapeutics, Inc.$44K
- Chugai Pharmaceutical Co., Ltd.$42K
- Sanofi-aventis U.S. LLC$40K
- plus $219K from 20 others
Across 61 payments — averaging $63,614 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3.8M
- AstraZeneca$44K
- Novartis$22K
- UCB SA$17K
- F. Hoffmann-la Roche AG$14K
- TG Therapeutics, Inc.$3K
- plus $1K from 1 others
What the payments were for
- Consulting fees$451,97758%
- Speaking & faculty fees$220,09828%
- Travel & lodging$92,21812%
- Food & beverage$5,3911%
- Education$3,1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 45 | $183,063 |
| Amgen(2 entities) | 86 | $151,837 |
| EMD Serono, Inc. | 66 | $92,640 |
| TG Therapeutics, Inc. | 34 | $44,308 |
| Chugai Pharmaceutical Co., Ltd. | 7 | $42,340 |
| Sanofi-aventis U.S. LLC | 7 | $39,985 |
| Genentech USA, Inc. | 21 | $39,208 |
| F. Hoffmann-la Roche AG | 16 | $39,071 |
| Novartis | 28 | $37,604 |
| Novartis Pharma AG | 15 | $20,147 |
| Sandoz | 7 | $18,490 |
| Genentech, Inc. | 6 | $16,694 |
| Cycle Pharmaceuticals Inc | 4 | $12,470 |
| Greenwich Biosciences, Inc. | 6 | $6,259 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,020 |
| Merck Kgaa | 2 | $5,278 |
| Sarepta Therapeutics, Inc. | 1 | $4,839 |
| Hexal AG | 2 | $4,274 |
| Bayer | 2 | $2,502 |
| Eisai Inc. | 3 | $1,762 |
| AstraZeneca | 2 | $1,440 |
| Johnson & Johnson | 1 | $1,320 |
| Bristol Myers Squibb | 2 | $842 |
| Biogen | 4 | $325 |
| Boehringer Ingelheim | 2 | $51 |
| Regeneron | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPLIZNA$150,541
- Enspryng$54,545
- BRIUMVI$43,647
- Non-Covered Product$21,618
- AUBAGIO$19,092
- OCREVUS$18,592
- BAF312A_MAYZENT_NEUROSCIENCE$12,931
- Tascenso ODT$7,150
- Evobrutinib$6,776
- Epidiolex$6,098
- KESIMPTA$5,942
- Nityr$5,320
- Elevidys$4,839
- GILENYA$4,389
- Mavenclad$2,795
- FTY720D_GILENYA_NEUROSCIENCE$2,460
- Leqembi$1,755
- ULTOMIRIS$1,440
- MAYZENT$1,330
- GLATOPA$625
How this compares
$772,811 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 23 | $304,527 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $185,156 |
| CopaxoneGlatiramer Acetate | 11 | $64,172 |
| Dalfampridine ErDalfampridine | 13 | $15,229 |
| Lisdexamfetamine Dimesylate | 19 | $5,077 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 28 | $1,090 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 36 | $975 |
| Gabapentin | 50 | $952 |
| Trazodone Hcl | 14 | $431 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $395 |
| Tramadol Hcl | 38 | $308 |
| Sodium Chloride0.9 % Sodium Chloride | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
- Ann BassSan Antonio$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.